AVALON

A CELIAC DISEASE STUDY

DO YOU HAVE CELIAC DISEASE AND ARE YOU INTERESTED IN PARTICIPATING IN A CLINICAL TRIAL?
Immune tolerance could be on the horizon, and YOU can help us learn more

Get Your Patient Form
Clinical Research Partners (7110 Forest Avenue, Suite 201, Richmond, VA 23226)
804-250-9859
Recruitment@ClinicalResearchRVA.com
Get Your Patient Form
Summary

The AVALON Study is a phase 1 clinical trial assessing VTP-1000 in adults with celiac disease. VTP-1000 is an investigational targeted immunotherapy designed to prevent or reduce celiac disease symptoms from accidental gluten exposure by promoting tolerance to gluten.

Age

18 - 65 Years

Qualifications

  • Have biopsy-confirmed celiac disease.
  • Have been on a gluten-free diet for 12+ months.
  • Live in the US.
  • Additional eligibility criteria apply.

Compensation

Compensation for time and travel may be available.

Meet Our Team

Our experienced team will guide you through the process

Meet the Team

Dr. Call, co-founder of Clinical Research Partners, serves as President. He is a Certified Principle Investigator

Robert S. Call, MD, CPI

President

Annette Bennett, co-founder of Clinical Research Partners, serves as Chief Executive Officer and Research Director. She

Annette Bennett

Chief Executive Officer

Bo Vaughan is a native of Richmond, VA and forward-thinking health care strategist with a

Bo Vaughan, MD, MSHA, CPI

Medical Director

Jeanette Weller

EVP of Contracts and Budgets

Caitlin Vining

Controller CCRP

Kelly Craighead, BS, RN, CCRC

Regulatory Affairs Director

Carly McLaughlin, PharmD

Director of Pharmacy PharmD